Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma.
Head and neck cancer is one of the leading causes of cancer-related deaths worldwide, and squamous cell carcinomas (HNSCC) account for the majority of these cases.
Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.
Blocking a newly identified "immune memory checkpoint" in immune cells could improve immunotherapy and help prevent cancers from recurring, according to new findings in mice and human samples by researchers at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.
Scientists have engineered natural killer immune cells that not only kill head and neck tumor cells in mice but also reduce the immune-suppressing myeloid cells that allow tumors to evade the immune response, according to a new study in eLife.
Patients who were unexpectedly hospitalized for dehydration, fever or other ailments while undergoing radiation treatment for head and neck cancers were at a higher risk for less favorable outcomes, a new study from Roswell Park Comprehensive Cancer Center reports.
The Damon Runyon Cancer Research Foundation has named four new Damon Runyon Clinical Investigators.
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute (OSUCCC - James) has identified a protein within certain immune cells that is required for optimal immune responses to cancer.
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Despite facing challenges such as limited access to personal protective equipment (PPE) following the COVID-19 outbreak, radiation oncology clinics quickly implemented safety and process enhancements that allowed them to continue caring for cancer patients, according to a new national survey from the American Society for Radiation Oncology (ASTRO).
The final results of the randomized phase two trial E3311 will be presented at the American Society of Clinical Oncology annual meeting, to occur virtually from May 29-31.
More than 65,000 Americans are diagnosed annually with head and neck cancer, which most often occurs inside the mouth and throat. For patients who undergo surgery to treat this cancer, guidelines recommend that prompt initiation of radiotherapy -- within six weeks -- is critical for best outcomes.
People who have recently experienced loss of smell are being urged to participate in a survey as a new global research group investigates the symptom as a marker of COVID-19.
Aspirin is associated with a reduction in the risk of developing several cancers of the digestive tract, including some that are almost invariably fatal, such as pancreatic and liver cancers.
A study published in the JAMA Otolaryngology-Head & Neck Surgery examines the effect of Medicaid expansion on head and neck cancer patients, finding that the expansions under the Affordable Care Act were associated with improved access to care for these patients and selective Medicaid expansion may worsen existing regional disparities in terms of access to care and outcomes.
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease - a point when many patients currently run out of options.
Joint research between Kobe University and National Hospital Organization Kyushu Cancer Center has revealed that mice with mutations in the YAP signal pathway develop head-and-neck cancer over an extremely short period of time (world's fastest cancer onset mouse model), indicating that this pathway plays a crucial role in the onset of these cancers.
Researchers at UC have discovered a previously unknown mechanism that could explain the reason behind decreased immune function in cancer patients and could be a new therapeutic target for immunotherapy for those with head and neck cancers.
It is estimated that as many as 80% of advanced-stage cancer patients may develop cachexia, a potentially fatal metabolic syndrome characterized by extreme weight loss and muscle wasting, but scientists do not yet fully understand why it is more frequently associated with certain kinds of tumor than others, or why not all cancer patients develop it.
A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma